HRP20120174T1 - Derivat policikličnog cinamida - Google Patents

Derivat policikličnog cinamida Download PDF

Info

Publication number
HRP20120174T1
HRP20120174T1 HR20120174T HRP20120174T HRP20120174T1 HR P20120174 T1 HRP20120174 T1 HR P20120174T1 HR 20120174 T HR20120174 T HR 20120174T HR P20120174 T HRP20120174 T HR P20120174T HR P20120174 T1 HRP20120174 T1 HR P20120174T1
Authority
HR
Croatia
Prior art keywords
group
methyl
phenyl
methoxy
vinyl
Prior art date
Application number
HR20120174T
Other languages
English (en)
Croatian (hr)
Inventor
Kimura Teiji
Kitazawa Noritaka
Kaneko Toshihiko
Sato Nobuaki
Kawano Koki
Ito Koichi
Doi Eriko
Takaishi Mamoru
Sasaki Takeo
Doko Takashi
Miyagawa Takehiko
Hagiwara Hiroaki
Original Assignee
Eisai R&D Management Co.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co. filed Critical Eisai R&D Management Co.
Publication of HRP20120174T1 publication Critical patent/HRP20120174T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
HR20120174T 2006-03-09 2007-03-08 Derivat policikličnog cinamida HRP20120174T1 (hr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US78051706P 2006-03-09 2006-03-09
JP2006063562 2006-03-09
US86170206P 2006-11-30 2006-11-30
JP2006322728 2006-11-30
PCT/JP2007/054532 WO2007102580A1 (fr) 2006-03-09 2007-03-08 Dérivé polycyclique de cinnamide

Publications (1)

Publication Number Publication Date
HRP20120174T1 true HRP20120174T1 (hr) 2012-03-31

Family

ID=38474999

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20120174T HRP20120174T1 (hr) 2006-03-09 2007-03-08 Derivat policikličnog cinamida

Country Status (15)

Country Link
EP (1) EP1992618B1 (fr)
KR (1) KR101464651B1 (fr)
AR (1) AR059955A1 (fr)
AU (1) AU2007223158B2 (fr)
CA (1) CA2643796A1 (fr)
CY (1) CY1112767T1 (fr)
EA (1) EA016464B1 (fr)
GE (1) GEP20115139B (fr)
HN (1) HN2008001374A (fr)
HR (1) HRP20120174T1 (fr)
IL (1) IL193770A (fr)
MA (1) MA30268B1 (fr)
MX (1) MX2008011221A (fr)
PL (1) PL1992618T3 (fr)
WO (1) WO2007102580A1 (fr)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0511504A (pt) 2004-05-26 2008-01-22 Eisai R&D Man Co Ltd composto ou um sal farmaceuticamente aceitável do mesmo, e, agente preventivo ou terapêutico para uma doença resultante de beta-amilóides
ATE458729T1 (de) 2004-10-26 2010-03-15 Eisai R&D Man Co Ltd Amorphe form einer zimtsäureamidverbindung
MY144960A (en) 2005-11-24 2011-11-30 Eisai R&D Man Co Ltd Morpholine type cinnamide compound
TWI370130B (en) 2005-11-24 2012-08-11 Eisai R&D Man Co Ltd Two cyclic cinnamide compound
TWI378091B (en) 2006-03-09 2012-12-01 Eisai R&D Man Co Ltd Multi-cyclic cinnamide derivatives
US7737141B2 (en) 2006-07-28 2010-06-15 Eisai R&D Management Co., Ltd. Prodrug of cinnamide compound
JP2010518080A (ja) * 2007-02-08 2010-05-27 メルク・シャープ・エンド・ドーム・コーポレイション 治療薬
US20080207900A1 (en) 2007-02-28 2008-08-28 Teiji Kimura Two cyclic oxomorphorin derivatives
AU2008250436B2 (en) 2007-05-11 2013-03-28 F. Hoffmann-La Roche Ag Hetarylanilines as modulators for amyloid beta
EP2152695A2 (fr) * 2007-06-01 2010-02-17 Schering Corporation Modulateurs de sécrétase gamma
ES2529648T3 (es) * 2007-08-31 2015-02-24 Eisai R&D Management Co., Ltd. Compuesto policíclico
US7935815B2 (en) * 2007-08-31 2011-05-03 Eisai R&D Management Co., Ltd. Imidazoyl pyridine compounds and salts thereof
EP2217604A1 (fr) 2007-11-05 2010-08-18 Schering Corporation Modulateurs de gamma-secrétase
WO2009076337A1 (fr) * 2007-12-11 2009-06-18 Schering Corporation Modulateurs de la gamma sécrétase
RU2527177C2 (ru) 2007-12-20 2014-08-27 Энвиво Фармасьютикалз, Инк. Четырехзамещенные бензолы
CA2705411A1 (fr) 2007-12-21 2009-07-02 F. Hoffmann-La Roche Ag Derives heteroaryles en tant qu'antagonistes du recepteur a orexine
KR101244517B1 (ko) 2008-01-11 2013-03-18 에프. 호프만-라 로슈 아게 아밀로이드 베타에 대한 조절제
AU2009216851B2 (en) 2008-02-22 2013-11-07 F. Hoffmann-La Roche Ag Modulators for amyloid beta
JP2012501336A (ja) * 2008-08-27 2012-01-19 エーザイ・アール・アンド・ディー・マネジメント株式会社 シンナミド化合物の製造法
WO2010040661A1 (fr) 2008-10-09 2010-04-15 F. Hoffmann-La Roche Ag Modulateurs pour l'amyloïde bêta
CA2742317A1 (fr) * 2008-11-06 2010-05-14 Schering Corporation Modulateurs de secretase gamma
JP2012508180A (ja) * 2008-11-06 2012-04-05 シェーリング コーポレイション γ−セクレターゼ調節剤
AU2009312856A1 (en) 2008-11-10 2010-05-14 F. Hoffmann-La Roche Ag Heterocyclic gamma secretase modulators
CA2742472A1 (fr) 2008-11-13 2010-05-20 Schering Corporation Modulateurs de gamma secretase
CA2747744A1 (fr) 2008-12-22 2010-07-01 Theodros Asberom Modulateurs de gamma secretase
TW201030002A (en) 2009-01-16 2010-08-16 Bristol Myers Squibb Co Bicyclic compounds for the reduction of beta-amyloid production
JP2012121809A (ja) * 2009-02-26 2012-06-28 Eisai R & D Management Co Ltd 多環式化合物の製造法およびその中間体
JP2012051805A (ja) 2009-02-26 2012-03-15 Eisai R & D Management Co Ltd テトラヒドロトリアゾロピリジン誘導体の製造方法
EP2401277A1 (fr) 2009-02-26 2012-01-04 Eisai R&D Management Co., Ltd. Sel de dérivé de tétrahydrotriazolopyridine et ses cristaux
JP2012051807A (ja) * 2009-02-26 2012-03-15 Eisai R & D Management Co Ltd アリールイミダゾール化合物
TW201035101A (en) * 2009-02-26 2010-10-01 Eisai R&D Man Co Ltd Nitrogen-containing fused heterocyclic compound
US20120142672A1 (en) 2009-07-13 2012-06-07 Tatsuki Koike Heterocyclic compound and use thereof
US8871760B2 (en) * 2009-09-21 2014-10-28 Roche Palo Alto Llc [1,2,4]triazolo[3,4-C][1,4]oxazines as P2X7 modulators
AU2011206635B2 (en) * 2010-01-15 2015-01-22 Cellzome Limited Novel substituted triazole derivatives as gamma secretase modulators
US8486967B2 (en) 2010-02-17 2013-07-16 Hoffmann-La Roche Inc. Heteroaryl substituted piperidines
US8513230B2 (en) 2010-03-05 2013-08-20 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
EP2611805A1 (fr) 2010-09-02 2013-07-10 Takeda Pharmaceutical Company Limited Triazoles fusionnés pour le traitement ou la prophylaxie du trouble cognitif léger
JP2014012641A (ja) * 2010-10-29 2014-01-23 Dainippon Sumitomo Pharma Co Ltd 新規ピリジン誘導体
CN103402359B (zh) * 2011-01-17 2016-08-24 卡尔约药物治疗公司 含烯烃核运输调节剂及其用途
EP2736887B1 (fr) 2011-07-29 2017-10-18 Karyopharm Therapeutics, Inc. Modulateurs de transport nucléaire contenant de l'hydrazide et leurs utilisations
EP2736883B1 (fr) 2011-07-29 2019-09-04 Karyopharm Therapeutics, Inc. Modulateurs de transport nucléaire et leurs utilisations
WO2013055793A1 (fr) 2011-10-12 2013-04-18 University Of Pittsburg-Of The Commonwealth System Of Higher Education Petites molécules ciblant la localisation et/ou le niveau nucléaire des récepteurs de l'androgène dans le cancer de la prostate
IN2014DN09434A (fr) 2012-05-09 2015-07-17 Karyopharm Therapeutics Inc
CN104583208B (zh) 2012-05-16 2016-09-28 杨森制药公司 可用于治疗(尤其是)阿尔茨海默病的取代的3,4-二氢-2H-吡啶并[1,2-a]吡嗪-1,6-二酮衍生物
EP2687528A1 (fr) * 2012-07-17 2014-01-22 Ares Trading S.A. Dérivés de triazole fusionnés comme modulateurs de gamma-sécrétase
AU2013366668B2 (en) 2012-12-20 2017-07-20 Janssen Pharmaceutica Nv Novel tricyclic 3,4-dihydro-2H-pyrido[1,2-alpha]pyrazine -1,6-dione derivatives as gamma secretase modulators
AU2014206834B2 (en) 2013-01-17 2017-06-22 Janssen Pharmaceutica Nv Novel substituted pyrido-piperazinone derivatives as gamma secretase modulators
WO2014144772A1 (fr) 2013-03-15 2014-09-18 Karyopharm Therapeutics Inc. Procédés de promotion de la cicatrisation d'une plaie à l'aide d'inhibiteurs de crm1
CN110386919B (zh) 2013-06-21 2023-07-14 卡尔约药物治疗公司 核转运调节剂及其用途
US20160257657A1 (en) 2013-09-20 2016-09-08 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer
EP3046561B1 (fr) 2013-09-20 2023-02-22 University of Pittsburgh - Of the Commonwealth System of Higher Education Composés destinés au traitement du cancer de la prostate
US10562897B2 (en) 2014-01-16 2020-02-18 Janssen Pharmaceutica Nv Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators
CN111484483B (zh) 2014-08-15 2023-05-26 卡尔约药物治疗公司 赛灵克斯的多晶型物
EP3397634A1 (fr) 2015-12-31 2018-11-07 Karyopharm Therapeutics, Inc. Modulateurs de transport nucléaire et leurs utilisations
US10526295B2 (en) 2015-12-31 2020-01-07 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
PL3419979T3 (pl) * 2016-02-23 2020-06-29 Pfizer Inc. Związki 6,7-dihydro-5h-pirazolo[5,1-b][1,3]oksazyno-2- karboksyamidowe
US10980806B2 (en) 2016-03-24 2021-04-20 University of Pittsburgh—of the Commonwealth System of Higher Education Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer
US11602530B2 (en) 2016-11-28 2023-03-14 Biogen Ma Inc. CRM1 inhibitors for treating epilepsy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE288898T1 (de) * 2000-12-04 2005-02-15 Hoffmann La Roche Phenylethenyl- oder phenylethinylderivate als glutamatrezeptorantagonisten
JP2006518738A (ja) * 2003-02-12 2006-08-17 トランス　テック　ファーマ，インコーポレイテッド 治療薬としての置換アゾール誘導体
US20050187277A1 (en) * 2004-02-12 2005-08-25 Mjalli Adnan M. Substituted azole derivatives, compositions, and methods of use
BRPI0511504A (pt) * 2004-05-26 2008-01-22 Eisai R&D Man Co Ltd composto ou um sal farmaceuticamente aceitável do mesmo, e, agente preventivo ou terapêutico para uma doença resultante de beta-amilóides

Also Published As

Publication number Publication date
GEP20115139B (en) 2011-01-10
EA016464B1 (ru) 2012-05-30
HK1122027A1 (en) 2009-05-08
CA2643796A1 (fr) 2007-09-13
HK1128085A1 (en) 2009-10-16
EP1992618B1 (fr) 2012-01-18
IL193770A0 (en) 2009-05-04
PL1992618T3 (pl) 2012-06-29
CY1112767T1 (el) 2016-02-10
KR20080108481A (ko) 2008-12-15
IL193770A (en) 2012-10-31
KR101464651B1 (ko) 2014-11-24
WO2007102580A1 (fr) 2007-09-13
MX2008011221A (es) 2008-09-11
EP1992618A4 (fr) 2010-11-10
AU2007223158B2 (en) 2012-04-12
AR059955A1 (es) 2008-05-14
HN2008001374A (es) 2011-03-15
EA200870336A1 (ru) 2009-02-27
AU2007223158A1 (en) 2007-09-13
MA30268B1 (fr) 2009-03-02
EP1992618A1 (fr) 2008-11-19

Similar Documents

Publication Publication Date Title
AU2019203444B2 (en) Bicyclic lactams and methods of use thereof
AU2019240299B2 (en) SHP2 phosphatase inhibitors and methods of use thereof
JP6382867B2 (ja) Ｔｒｋａキナーゼ阻害剤としてのピロリジニル尿素およびピロリジニルチオ尿素化合物
AU2011240808B2 (en) 5, 7-substituted-imidazo [1, 2-c] pyrimidines as inhibitors of JAK kinases
JP2022533120A5 (fr)
CN114945571B (zh) 环状化合物及其使用方法
ES2550201T3 (es) Moduladores de la PDE10
JP6785384B2 (ja) 新規なヘテロ環化合物、その製造方法およびこれを含む薬学的組成物
CA2694401A1 (fr) Compose polycyclique
JP2011516512A5 (ja) 新規な置換スピロ[シクロアルキル−１,３'−インドール]−２'(１'Ｈ)−オン誘導体およびｐ３８マイトジェン活性化タンパク質キナーゼ阻害剤としてのそれらの使用
JP2019504821A (ja) ユビキチン特異的プロテアーゼ１阻害剤としてのプリノン
BG107899A (bg) Б...нзимидазолови и пиридилимидазолови производни ка'о лиганди на gaba р...-...п'ори
HUE032770T2 (en) Novel nk-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in nk-3 receptors mediated disorders
RU2005117383A (ru) Производные фенилаланина в качестве ингибиторов дипептидилпептидазы для лечения или профилактики диабета
CA2521929A1 (fr) Derives bicycliques, leur preparation, compositions pharmaceutiques les contenant et leur usage therapeutique
IL295076B2 (en) Piperidinone derivatives as MDM2 inhibitors for cancer treatment
HRP20160649T1 (hr) Novi derivati tienopirimidina, postupci za njihovo pripremanje i njihova terapeutska uporaba
HRP20250272T1 (hr) Derivati benzimidazola i njihova uporaba
RU2020114670A (ru) Бициклические соединения для применения в качестве ингибиторов rip1 киназы
JP2024512740A (ja) 例えばがんの処置のためのＳＨＰ２阻害剤としての（Ｓ）－１－（５－（（ピリジン－３－イル）チオ）ピラジン－２－イル）－４’Ｈ，６’Ｈ－スピロ［ピペリジン－４，５’－ピロロ［１，２－ｂ］ピラゾール］－４’－アミン誘導体及び同様の化合物
JP2025081381A5 (fr)
US12180226B2 (en) Spirotricycle RIPK1 inhibitors and methods of uses thereof
CA3243942A1 (fr) Nouveaux composés bicycliques en tant qu'inhibiteurs de rad51
TH2101006978A (th) สารยับยั้งการกินตัวเองของเซลล์ชนิดเฮเทอโรแอริลอะมิโนไพริดีนเอไมด์และวิธีการใช้สารนั้น
NZ737297B2 (en) Bicyclic lactams and methods of use thereof